. Author manuscript; available in PMC: 2017 Jan 6.

Published in final edited form as: Crit Rev Biochem Mol Biol. 2016 Jan 6;51(1):65–71. doi: 10.3109/10409238.2015.1128875

Table 2.

Genetically engineered mouse models available for study of RAMP function in vivo.

	Mouse Model	RAMP1	RAMP2	RAMP3
LOSS OF FUNCTION	Global	*Ramp1^−/−* (Li et al., 2014, Tsujikawa et al., 2007)	*(Ramp2^+/−)^ (Dackor et al., 2007)	*Ramp3^−/−* (Dackor et al., 2007)
	Tissue-specific	N/A	Endothelial (VE-Cad) (Koyama et al., 2013)	N/A
	Drug-inducible, tissue-specific	N/A	Cardiomyocyte (αMHC) (Yoshizawa et al., 2013) Endothelial (VE-Cad) (Koyama et al., 2013)	N/A
GAIN OF FUNCTION	Global transgenic	hRAMP1 (Zhang et al., 2007)	N/A	N/A
GAIN OF FUNCTION	Tissue-specific transgenic	Neuronal (Chrissobolis et al., 2010)	N/A	N/A
GPCR INTERACTIONS ADDRESSED		CLR	CLR CTR CRF Glucagon Receptor PTHR1	CLR GPER

Ramp2^−/− mice are embryonic lethal (Caron and Smithies, 2001).